BIOPHYTIS (EPA:ALBPS) - Biophytis Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Transparency directive : regulatory news

07/12/2018 18:00

Press release

Biophytis Announces One Oral Presentation and Two Poster Presentations at the
11th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Paris (France), December 7, 2018, 6pm - BIOPHYTIS (Euronext Growth Paris:
ALBPS), a clinical-stage biotechnology company developing first-in-class drug
candidates for the treatment of age-related degenerative diseases, today
announced that abstracts highlighting the Company's lead candidate, SARCONEOS
(BIO101) will be presented at the 11th International Conference on Cachexia,
Sarcopenia and Muscle Wasting, being held between December 7-9, 2018 in
Maastricht, Netherlands.

Stanislas Veillet, Ph.D., chief executive officer of Biophytis stated, "We are
pleased with these preclinical results that demonstrate SARCONEOS accelerates
skeletal muscle cell differentiation from stem cells and increases their
energetic metabolism. These specific effects, combined with the stimulation of
muscle protein synthesis, explain the significant effect of SARCONEOS on muscle
mass, muscle strength and mobility, in animal models of muscular
dystrophies."

Dr. Veillet continued, "In addition, we are pleased to announce the completion
of patients recruitment in the SARA-OBS observational study of SARCONEOS. These
patients will be eligible to participate to the SARA-INT double-blind, placebo
controlled, randomized Phase 2b clinical study in sarcopenia in sites in both
the U.S. and Europe. 9 clinical centers are now open in SARA-INT."

Details of the oral and poster presentations are as follows:

Oral Presentation
Title: BIO101 accelerates differentiation and enhances mitochondrial function
in skeletal muscle cells
Presenter: Maria Serova, Ph.D.
Session: D. Late breaking clinical science & clinical trial update
Date/Time: Saturday, December 10, 2018 at 11:00 a.m. CEST
Location: Ceramique, Crowne Plaza Hotel, Netherlands

Poster Presentations
Title: BIO101 accelerates differentiation and enhances mitochondrial function
in skeletal muscle cells
Presenter: Maria Serova, Ph.D.
Poster: 4-11
Session: 5

Date/Time: Saturday 8th of December 2018, 11 AM
Location: Poster Area, Crowne Plaza Hotel, Netherlands

Title: Transitioning from SARA-OBS, an observational study to SARA-INT, a
double-blind, placebo controlled, randomized clinical trial to evaluate safety
and efficacy of SARCONEOS (BIO101)
Presenter: Waly Dioh, Ph.D. Poster: P5-001
Session: 12
Date/Time: Sunday 9th of December 2018, 10 AM
Location: Poster Area, Crowne Plaza Hotel, Netherlands

About SARCONEOS
Biophytis's lead candidate, SARCONEOS, is a first-in-class drug candidate
formulated to activate the MAS receptor for the treatment of neuromuscular
diseases. SARCONEOS is currently being tested in a Phase 2b clinical trial to
preserve muscle strength, performance and patient mobility in sarcopenia, a
degenerative disease characterized by loss of muscle mass, quality, and
strength associated with aging that affects up to 50 million elderly people. In
addition, Biophytis is preparing for the clinical development of SARCONEOS in
children with DMD, which received orphan drug designation in 2018 from both the
FDA and EMA.

About BIOPHYTIS
Biophytis SA, founded in 2006, is a biotechnology company specializing in the
development of drug candidates to treat the disabilities caused by age-related
degenerative diseases. Our clinical-stage pipeline is comprised of SARCONEOS, a
MAS receptor activator, to preserve mobility in sarcopenia and Duchenne
muscular dystrophy (DMD) patients and MACUNEOS, a drug that binds PPAR to
prevent vision loss in patients with dry age-related macular degeneration (AMD)
and other degenerative eye diseases, including Stargardt disease.
Biophytis is based in Paris on the Sorbonne Université campus and in
Cambridge, Massachusetts. Biophytis collaborates with expert scientists from
several Sorbonne Université institutes including the Paris Seine Biology
Institute, the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
ISIN: FR0012816825).

For more information: http://www.biophytis.com

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

Disclaimer

This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain forward-
looking statements involving risks and uncertainties. The Company's actual
results could differ substantially from those anticipated in these statements
owing to various risk factors which are described in the Company's prospectus.
This press release has been prepared in both French and English. In the event
of any differences between the two texts, the French language version shall
prevail.

BIOPHYTIS
Stanislas VEILLET
CEO
contact@biophytis.com
Tel: +33 (0) 1 44 27 23 00

LifeSci Public Relations
Cherilyn CECCHINI, M.D.
U.S. Media Contact
ccecchini@lifescipublicrelations.com
Tel: +1 (646) 876 5196

Citigate Dewe Rogerson
International media & Investors
Laurence BAULT/Antoine DENRY
Laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogreson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61

LifeSci Advisors
Chris MAGGOS
Managing Director, Europe
chris@lifesciadvisors.com
Tel: +41 79 367 6254

BIOPHYTIS's latest news

18/04/2024 07:02

BIOPHYTIS (EPA:ALBPS) - Biophytis Announces One Oral Presentation and Two Poster Presentations at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories